Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $0.04 by 572.22 percent. This is a 183.33 percent decrease over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $13.777 million which missed the analyst consensus estimate of $13.993 million by 1.55 percent. This is a 73.84 percent increase over sales of $7.925 million the same period last year.